ArticleTherapeutic advances in gastroenterology2026
Efficacy and safety of risankizumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) is a chronic inflammatory disorder with limited therapeutic options for treatment-refractory patients. This meta-analysis evaluates the efficacy and safety of risankizumab (IL-23 p19 inhibitor) in moderate-to-severe CD. Objectives: To evaluate the clinical, endoscopic, and safety outcomes of risankizumab in patients with moderate-to-severe CD. Design: Systematic review and meta-analysis of randomized controlled trials (RCTs). Data sources and methods: A systematic search identified seven RCTs evaluating risankizumab at different doses, including a total of 4411 patients. We searched multiple databases, including PubMed, Cochrane CENTRAL, ClinicalTrials.gov, and Web of Science. Outcomes included clinical and endoscopic remission, endoscopic response, mucosal healing, stool frequency and abdominal pain scores. Data were pooled using a random-effects model, with risk ratios (RRs) and 95% confidence intervals (CIs) reported. Separate meta-analyses were conducted for the induction and maintenance phases. Results: Risankizumab was significantly more effective than placebo or active comparator in achieving clinical remission (CDAI) during induction (RR, 1.85; 95% CI, 1.69-2.01; Conclusion: These findings suggest that risankizumab is an effective and safe option for inducing and maintaining remission in moderate-to-severe CD. Further long-term studies should refine dosing, assess long-term outcomes, and support its integration into clinical guidelines. Trial registration: PROSPERO ID: CRD42024611707.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.